ライフサイエンスコーパス: following therapy

1 asticity in the primary somatosensory cortex following therapy.

2 ome measure for recovery of binocular vision following therapy.

3 m, and Corynebacterium species were observed following therapy.

4 ons were carried out at baseline and 8 weeks following therapy.

5 mplete resolution of Guillain-Barre syndrome following therapy.

6 n imaging data were acquired at baseline and following therapy.

7 t high frequencies (42 to 50%) 70 to 90 days following therapy.

8 epeat liver biopsy were assessed at 24 weeks following therapy.

9 of Aa at baseline as well as 3 and 12 months following therapy.

10 se activity during the study or in the month following therapy.

11 oups and HGV was not associated with outcome following therapy.

12 mined during the course of HIV infection and following therapy.

13 were measured at baseline and 6 and 9 months following therapy.

14 g indolent phases, and undergo rapid changes following therapy.

15 patients under 60 years of age received the following therapy: 45 mg/m(2) daunorubicin on days 1-3,

16 s perceived their disease to be in remission following therapy, 78% of these patients required contin

17 atients who recovered from HCV infection (98 following therapy and 19 spontaneously).

18 pain and paraesthesia symptoms at baseline, following therapy and at 3-month follow-up.

19 from the end of the successful weaning trial following therapy and the previously failed one, were an

20 ll clones, elimination of clonal populations following therapy, and subsequent appearance of a clone

21 Following therapy, aortic TBR fell to 1.90+/-0.29, P=0.0

22 t therapy, and patients with detectable DTCs following therapy are at substantially increased risk fo

23 Malignant carcinomas that recur following therapy are typically de-differentiated and mu

24 KLF4 at disease acceleration, which resolves following therapy, but reoccurs following relapse and de

25 ng period, the defects were treated with the following therapies: collagen membrane (GTR), human demi

26 ibute to the survival of breast cancer cells following therapy could aid in the development of more e

27 immunomodulators, and predictors of relapse following therapy discontinuation have become available.

28 viral therapy era; however, data on outcomes following therapy for anal dysplasia (infrared coagulato

29 delines are commonly used to assess response following therapy for hepatocellular carcinoma (HCC).

30 to 12 days, 35 to 45 days, and 70 to 90 days following therapy for quantitative vaginal culture.

31 ion that gonococcal DNA is detectable by LCR following therapy for uncomplicated gonococcal infection

32 cted an increase in Ki-67+ PD-1+ CD8 T cells following therapy in approximately 70% of patients, and

33 GCF chemerin and IL-6 levels decreased following therapy in CP groups (P <0.02).

34 nd to analyze changes in cytokine expression following therapy in order to understand its primary mec

35 nt was numerically higher at all time points following therapy in the 500 mg rituximab group.

36 mice harbored abnormal lymphoproliferations following therapy--in these cases, comparison of the loc

37 the assessments of minimal residual disease following therapy, including for patients who have under

38 ed by diverse therapy-sensitive cancer cells following therapy-induced caspase cleavage of the tumor

39 g the persistence of disparities in survival following therapy initiation is mixed.

40 inations at baseline and within three months following therapy initiation were assessed.

41 mycin-resistant anaerobic gram-negative rods following therapy is of concern.

42 At 3 and 12 months following therapy mean PD at monitored sites in the test

43 the sensory scale of the SF-MPQ was reduced following therapy (P=0.02).

44 ssessment of restoration of retinal function following therapy renders achromatopsia a very attractiv

45 (IgE) and other Th2 responses in the months following therapy, responses that have been associated w

46 ividuals experiencing serious adverse events following therapy (see the related articles beginning on

47 showing a time-dependent response up to 3 h following therapy, suggesting a diffusion of soluble Fas

48 ared with T1DM patients and can be monitored following therapies targeted at improving inflammation a

49 Following therapy, Th17 cells were essentially lost, whe

50 eventual secondary decline of DP thymocytes following therapy was associated with renewed viral expr

51 In contrast, initial tumor regression following therapy was unimpaired in CD1d(-/-) mice, whic

52 Surgical specimens following therapy were assessed for the degree of pathol

53 lapse) and 10 patients with no response (NR) following therapy were identified through the Virahep-C

54 ite APBI developed peak distortion 21 months following therapy, which may be sooner than distortion f

55 rinary storage symptoms (overactive bladder) following therapy with an alpha-blocker, the addition of

56 ssociated with DNA-damaging agents can occur following therapy with FND, with or without rituximab, a

57 cant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.

58 myeloid leukemia (CML) SCs that is enriched following therapy with tyrosine kinase inhibitors (TKIs)

59 hat the reduction of DMN-insula connectivity following therapy would correlate with diminished pain.